Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0SLLFJ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
BCG022
|
|||||
| Synonyms |
BCG 022; BCG-022
Click to Show/Hide
|
|||||
| Organization |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 4 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Clinical candidate
Colorectal cancer [ICD11:2B91]
Clinical candidate
Gastric cancer [ICD11:2B72]
Clinical candidate
Non-small cell lung cancer [ICD11:2C25]
Clinical candidate
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-3 (ERBB3); Hepatocyte growth factor receptor (MET)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.